Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Nebraska |
---|---|
Information provided by: | University of Nebraska |
ClinicalTrials.gov Identifier: | NCT00876226 |
This prospective study will determine the pharmacokinetic parameters of citalopram in 12 adult patients with short bowel syndrome. While data on the prevalence of depression in patients with short bowel syndrome is sparse, the investigators' experience is that these patients have a high incidence of depression and should benefit from a psychopharmacological intervention.
Condition | Intervention |
---|---|
Short Bowel Syndrome |
Drug: Citalopram |
Study Type: | Interventional |
Study Design: | Health Services Research, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | Study to Determine Steady-State Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome |
Estimated Enrollment: | 12 |
Study Start Date: | June 2009 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.
Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose.
Ages Eligible for Study: | 19 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ashish Sharma, MD | 402-552-2112 ext 2168 | asharma2@unmc.edu |
United States, Nebraska | |
University of Nebraska Medical Center | |
Omaha, Nebraska, United States, 68198-8470 |
Principal Investigator: | Ashish Sharma, MD | University of Nebraska |
Responsible Party: | The Nebraska Medical Center ( Ashish Sharma ) |
Study ID Numbers: | 479-07-FB |
Study First Received: | April 2, 2009 |
Last Updated: | April 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00876226 History of Changes |
Health Authority: | United States: Institutional Review Board |
Citalopram Pharmacokinetics Short Bowel Syndrome |
Neurotransmitter Agents Cholinergic Antagonists Gastrointestinal Diseases Psychotropic Drugs Short Bowel Syndrome Cholinergic Agents Intestinal Diseases Citalopram Serotonin Uptake Inhibitors |
Serotonin Muscarinic Antagonists Digestive System Diseases Postoperative Complications Malabsorption Syndromes Peripheral Nervous System Agents Dexetimide Antidepressive Agents, Second-Generation Antidepressive Agents |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents Pathologic Processes Syndrome Therapeutic Uses Antidepressive Agents, Second-Generation |
Dexetimide Antidepressive Agents Disease Short Bowel Syndrome Intestinal Diseases Citalopram Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Digestive System Diseases Serotonin Agents Postoperative Complications Autonomic Agents Malabsorption Syndromes Peripheral Nervous System Agents |